Financials data is unavailable for this security.
View more
Year on year Tibet Rhodiola Pharmaceutical Holding Co grew revenues 22.69% from 2.55bn to 3.13bn while net income improved 116.56% from 369.84m to 800.91m.
| Gross margin | 93.36% |
|---|---|
| Net profit margin | 25.22% |
| Operating margin | 28.17% |
| Return on assets | 15.80% |
|---|---|
| Return on equity | 20.92% |
| Return on investment | 20.83% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Tibet Rhodiola Pharmaceutical Holding Co fell by 245.11m. However, the company earned 1.06bn from its operations for a Cash Flow Margin of 33.93%. In addition the company used 831.88m on investing activities and also paid 483.69m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 11.26 |
|---|---|
| Tangible book value per share | 10.67 |
More ▼
Balance sheet in CNYView more
| Current ratio | 3.58 |
|---|---|
| Quick ratio | 3.44 |
| Total debt/total equity | 0.1461 |
|---|---|
| Total debt/total capital | 0.1264 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 159.92% and 116.80%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 1.89% |
|---|---|
| Div growth rate (5 year) | 48.97% |
| Payout ratio (TTM) | 67.04% |
| EPS growth(5 years) | 30.38 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 6.21 |
More ▼
